Project Description

OECD 488: Big Blue® In Vivo Transgenic Mutation Assay

Gentronix Ltd has expanded its genetic toxicology capabilities by acquisition of the Big Blue® transgenic mutation assay models from Merck KGaA, Darmstadt, Germany in June 2021.

SERVICE INFORMATION

The acquisition of the Big Blue® transgenic mutation models ensures continued market provision of the Big Blue® transgenic assays for companies requiring mutagenicity assessment under the OECD 488 guideline. These studies play a central role in enabling risk assessments for materials where pre-existing data indicates a potential mutagenicity risk to human health and the environment.  The transfer of the technology and establishment of Gentronix laboratory proficiency are now underway, which will ensure continuity of this important service offering.

The acquisition allows us to strengthen the Gentronix portfolio of OECD guideline genetic toxicology testing services while we are also increasing our capacity within existing service offerings. The addition of the Big Blue® transgenic mutation assays is another significant step forward for our business, enhancing our credentials as the leading specialist genetic toxicology contract research organisation.

We now have the capability to support clients from their very first genetic toxicology screens right through to helping manage complex mutagenicity risk assessments. If you would like more details on how Gentronix can support your project through conduct of OECD 488 Big Blue® transgenic mutation assays please contact a member of the team today.

Talk to a Toxicologist

Predictive Toxicology, Expertly Delivered

GET IN TOUCH